Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13
pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer
on active surveillance who have not received treatment. Diagnostic procedures, such as MRI,
may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Cancer Institute (NCI) National Institute for Biomedical Imaging and Bioengineering (NIBIB)